We think that the blood flow increases during intraarterial injection of a special drug, called iloprost, during surgical treatment in the distal limbs, because of the vasodilatation in diabetics and non diabetics in the same way.

Conditions: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way because of vasodilatation. So we investigate people with arteriosclerosis and diabetes and non diabetes which undergo surgical treatment.
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]

Registration Number: EUCTR2011-004567-80-AT

Lead Sponsor: Georg Hagmüller Institute for Vascular Research

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

patients between 18-99 years, women, men, patients with diabetes and non-diabetes, patients with arteriosclerosis and who undergo surgical treatment in distal vessels
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

pregnancy, heart attack, stroke in the last 6 months, hypotension, edema of the lungs, heart failure, heart diseases, COPD, ulcus ventriculi, renal diseases, coronary diseases, immaturity

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way because of vasodilatation. ;Timepoint(s) of evaluation of this end point: 2 years;Primary end point(s): We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Secondary Objective: We don`t think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): We don`t think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Timepoint(s) of evaluation of this end point: 2 years